Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors

DISEASE CHARACTERISTICS: * Histologically proven recurrent or refractory pediatric solid tumor * Bone marrow metastases allowed PATIENT CHARACTERISTICS: Age: * 1 to 30 Performance status: * 0-2 Life expectancy: * At least 2 months Hematopoietic: * Absolute neutrophil count at least 1,000/mm3 * Platelet count at least 100,000/mm3 (transfusion independent) * Hemoglobin at least 10 g/dL (RBC transfusion allowed) Hepatic: * Bilirubin no greater than 1.5 times normal * SGOT no greater than 2.5 times normal Renal: * Adequate renal function as defined by one of the following: * GFR by creatinine clearance * Radioisotope GFR * Iothalamate at least 70 mL/min Cardiovascular: * Adequate cardiac function as defined by one of the following: * Ejection fraction at least 55% by MUGA * Fractional shortening at least 28% by echocardiogram Neurologic: * Adequate CNS function as defined by: * Seizure disorder, if present, controlled by anticonvulsants * CNS toxicity no greater than grade 2 Other: * No uncontrolled infections * Not pregnant or nursing * No allergy to platinum compounds * No history of allergy to etoposide (unless mobilization phase not required) PRIOR CONCURRENT THERAPY: Biologic therapy: * Recovered from prior immunotherapy * At least 1 week since prior cytokines * At least 3 months since prior bone marrow or peripheral blood stem cell transplantation * No concurrent immunomodulator * No concurrent cytokines Chemotherapy: * At least 3 weeks (6 for nitrosourea) since prior chemotherapy and recovered * No prior thiotepa * No other concurrent chemotherapy Endocrine therapy: * Not specified Radiotherapy: * Recovered from prior radiotherapy * At least 6 months since prior total body irradiation conditioning * No concurrent radiotherapy to greater than 10% of total liver, lung, or bone marrow Surgery: * Not specified